MX371430B - Composicion que comprende una mezcla de isoformas cd95-fc. - Google Patents

Composicion que comprende una mezcla de isoformas cd95-fc.

Info

Publication number
MX371430B
MX371430B MX2015000731A MX2015000731A MX371430B MX 371430 B MX371430 B MX 371430B MX 2015000731 A MX2015000731 A MX 2015000731A MX 2015000731 A MX2015000731 A MX 2015000731A MX 371430 B MX371430 B MX 371430B
Authority
MX
Mexico
Prior art keywords
composition
mixture
isoforms
domain
fusion protein
Prior art date
Application number
MX2015000731A
Other languages
English (en)
Other versions
MX2015000731A (es
Inventor
Hill Oliver
Gieffers Christian
Thiemann Meinolf
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of MX2015000731A publication Critical patent/MX2015000731A/es
Publication of MX371430B publication Critical patent/MX371430B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a una composición caracterizada porque comprende una mezcla de isoformas de proteína de fusión, cada proteína de fusión comprende al menos un dominio CD95 extracelular o un fragmento funcional del mismo y al menos un dominio Fc o un fragmento funcional del mismo distribuido dentro de un rango pl de 4.0-8.5, en donde la proteína de APG101, un polipéptido que tiene al menos 95% de identidad a APG101 y/o un fragmento funcional de APG101, y en donde la mezcla inhibe la apoptosis. .
MX2015000731A 2012-07-18 2013-07-18 Composicion que comprende una mezcla de isoformas cd95-fc. MX371430B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176980 2012-07-18
EP12176978 2012-07-18
PCT/EP2013/065250 WO2014013039A1 (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Publications (2)

Publication Number Publication Date
MX2015000731A MX2015000731A (es) 2015-09-04
MX371430B true MX371430B (es) 2020-01-30

Family

ID=48794121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000731A MX371430B (es) 2012-07-18 2013-07-18 Composicion que comprende una mezcla de isoformas cd95-fc.

Country Status (18)

Country Link
US (5) US9315570B2 (es)
EP (4) EP3409686B1 (es)
JP (2) JP6317739B2 (es)
KR (1) KR102201694B1 (es)
CN (3) CN104640876A (es)
AU (2) AU2013291984B2 (es)
BR (1) BR112015000732B1 (es)
CA (2) CA2878992C (es)
DK (2) DK3409686T3 (es)
ES (2) ES2924109T3 (es)
HK (2) HK1207095A1 (es)
IL (1) IL236659A (es)
MX (1) MX371430B (es)
NZ (1) NZ703546A (es)
RU (2) RU2648157C2 (es)
SG (1) SG11201500134QA (es)
UA (1) UA116889C2 (es)
WO (2) WO2014013037A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703546A (en) * 2012-07-18 2018-03-23 Apogenix Ag Composition comprising a mixture of cd95-fc isoforms
BR112015027249A2 (pt) * 2013-04-29 2017-09-26 Apogenix Gmbh método de diagnóstico de câncer
NO2776305T3 (es) 2014-04-23 2018-01-27
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
CN114269370A (zh) 2019-03-29 2022-04-01 迈斯特治疗公司 离体产生t细胞治疗剂的方法以及相关的组合物和方法
EP4065229A1 (en) 2019-11-27 2022-10-05 Myst Therapeutics, LLC Method of producing tumor-reactive t cell composition using modulatory agents
KR20220097990A (ko) * 2019-12-12 2022-07-08 이엠디 밀리포어 코포레이션 정용여과 완충제를 사용한 강화된 바이러스 여과
EP4110799A1 (en) 2020-02-27 2023-01-04 Myst Therapeutics, LLC Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2650597A (en) * 1996-05-02 1997-11-26 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivatives
ATE273713T1 (de) * 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
DE69839582D1 (de) * 1997-02-27 2008-07-17 Ono Pharmaceutical Co Neues polypeptid, dafür kodierende dna und deren verwendungen
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
WO2004085479A2 (en) * 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
EP2004216A4 (en) * 2006-03-28 2012-02-01 Molecular Discovery Systems AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
EP2428252B1 (en) * 2006-12-28 2014-11-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
US8592557B2 (en) * 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
WO2010078966A1 (en) * 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
WO2011010156A1 (en) * 2009-07-21 2011-01-27 Queen Mary & Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
NZ703546A (en) * 2012-07-18 2018-03-23 Apogenix Ag Composition comprising a mixture of cd95-fc isoforms
BR112015027249A2 (pt) 2013-04-29 2017-09-26 Apogenix Gmbh método de diagnóstico de câncer

Also Published As

Publication number Publication date
EP3409686B1 (en) 2022-04-13
AU2013291984A1 (en) 2015-02-05
ES2674662T3 (es) 2018-07-03
WO2014013039A1 (en) 2014-01-23
RU2648157C2 (ru) 2018-03-22
JP2015524403A (ja) 2015-08-24
DK2875045T3 (en) 2018-07-02
WO2014013037A1 (en) 2014-01-23
US20150225475A1 (en) 2015-08-13
CA2877989A1 (en) 2014-01-23
UA116889C2 (uk) 2018-05-25
JP2015528006A (ja) 2015-09-24
US20160362471A1 (en) 2016-12-15
EP2875044B1 (en) 2018-04-11
CN109897115A (zh) 2019-06-18
HK1207095A1 (en) 2016-01-22
MX2015000731A (es) 2015-09-04
US9657083B2 (en) 2017-05-23
US9908928B2 (en) 2018-03-06
CN104640876A (zh) 2015-05-20
IL236659A0 (en) 2015-02-26
EP3406630A1 (en) 2018-11-28
US9315570B2 (en) 2016-04-19
EP3406630B1 (en) 2020-09-02
SG11201500134QA (en) 2015-03-30
RU2015105328A (ru) 2016-09-10
AU2013291982B2 (en) 2017-01-12
AU2013291984B2 (en) 2018-01-18
US10370441B2 (en) 2019-08-06
US20160235815A1 (en) 2016-08-18
CN104662039B (zh) 2019-10-08
EP2875045A1 (en) 2015-05-27
JP6317739B2 (ja) 2018-04-25
EP2875045B1 (en) 2018-03-28
BR112015000732A2 (es) 2017-08-15
CA2878992A1 (en) 2014-01-23
RU2015105330A (ru) 2016-09-10
ES2924109T3 (es) 2022-10-04
US9434783B2 (en) 2016-09-06
HK1207096A1 (en) 2016-01-22
EP2875044A1 (en) 2015-05-27
IL236659A (en) 2017-02-28
EP3409686A1 (en) 2018-12-05
KR102201694B1 (ko) 2021-01-12
NZ703546A (en) 2018-03-23
DK3409686T3 (da) 2022-07-18
US20180186856A1 (en) 2018-07-05
JP6231562B2 (ja) 2017-11-15
US20150166633A1 (en) 2015-06-18
CN104662039A (zh) 2015-05-27
AU2013291982A1 (en) 2015-02-05
RU2648146C2 (ru) 2018-03-22
CA2878992C (en) 2020-09-22
BR112015000732B1 (pt) 2023-01-10
KR20150048120A (ko) 2015-05-06
CA2877989C (en) 2021-05-25

Similar Documents

Publication Publication Date Title
NZ703546A (en) Composition comprising a mixture of cd95-fc isoforms
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
UA116092C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12014501108A1 (en) Anti-il-36r antibodies
MX350773B (es) Métodos y composiciones para el control de malezas.
UA116090C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
EA201591748A1 (ru) Модуляторы p2x7
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
MX357496B (es) Moduladores del receptor de estrógenos fluorados y sus usos.
EA201590887A1 (ru) Композиция
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2015005231A (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
PH12014501891B1 (en) Substituted chroman compounds as calcium sensing receptor modulators
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
IN2014DN10135A (es)
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2012158493A3 (en) Compounds that bind to the erythropoietin receptor
WO2014052717A3 (en) Cd20-and egfr-binding proteins enhanced stability

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NUOVO PIGNONE TECNOLOGIE - S.R.L.

Owner name: SCHAEFFLER TECHNOLOGIES AG & CO. KG.*

FG Grant or registration